Biji Chatterjee

This study shows ATRX loss in sarcomas correlates with poor outcomes and identifies TEAD inhibition as a potential therapy for ATRX-deficient tumors.

This study identifies ellagic acid as an inhibitor of EZH2 and PRMT5:MEP50, showing reduced histone modifications and tumor growth in mouse models.

This study shows that EGCG inhibits PRMT5 and EZH2 in breast cancer cells and xenografts, reducing histone repressive marks and inducing apoptosis and autophagy.

This study shows that nerve injury represses Oprd1 and Cnr1 transcription via REST in primary sensory neurons, suggesting REST as a therapeutic target for neuropathic pain.